This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190107005286/en/
“Access to the Inhibrx sdAb binder technology will allow us to combine the advancements we’ve made with our T cell therapy platform with their sdAb binder technology to generate novel cellular therapies with the potential to help patients in their fight against cancer,” said Philip Gregory, D. Phil., chief scientific officer, bluebird bio. “The technology from Inhibrx adds to our growing portfolio of tools and technologies that we can combine with our internal lentiviral vector, CAR and T cell expertise to discover potential new product candidates designed to recognize tumor-specific proteins expressed by cancer cells and kill them upon engagement.”
“We are pleased to have formalized our relationship with bluebird bio,
allowing us to couple our proprietary sdAb platform with a leading cell
therapy platform,” said
Under the terms of the license agreement, Inhibrx will provide bluebird
bio the exclusive worldwide rights to develop, manufacture and
commercialize certain cell therapy products containing sdAbs directed to
various cancer targets. bluebird bio will be responsible for the
clinical development and commercialization of the cancer-targeting CAR-T
products. Inhibrx received a
Inhibrx is a clinical-stage biotechnology company focused on developing
a broad pipeline of novel biologic therapeutic candidates. Inhibrx
utilizes diverse methods of protein engineering to address the specific
requirements of complex target and disease biology, including its
proprietary sdAb platform. The Inhibrx pipeline is focused on oncology,
orphan diseases and infectious diseases. Inhibrx has a collaboration
About bluebird bio, Inc.
With its lentiviral-based gene therapies, T cell immunotherapy expertise and gene editing capabilities, bluebird bio has built a pipeline with broad potential application in severe genetic diseases and cancer.
bluebird bio's gene therapy clinical programs include investigational treatments for cerebral adrenoleukodystrophy, transfusion-dependent β-thalassemia and sickle cell disease.
bluebird bio's oncology pipeline is built upon the company's lentiviral gene delivery and T cell engineering, with a focus on developing novel T cell-based immunotherapies, including chimeric antigen receptor (CAR T) and T cell receptor (TCR) therapies. The company’s lead oncology programs are anti-BCMA CAR T programs partnered with Celgene.
bluebird bio’s discovery research programs include utilizing megaTAL/homing endonuclease gene editing technologies with the potential for use across the company's pipeline.
bluebird bio has operations in Cambridge, Massachusetts; Seattle, Washington; Durham, North Carolina and Zug, Switzerland. For more information, visit bluebirdbio.com.
bluebird bio Forward-Looking Statements
This release contains “forward-looking statements” within the meaning
of the Private Securities Litigation Reform Act of 1995, including
statements regarding the research, development and advancement of
bluebird bio’s potential product candidates and research program, and
the benefits of each company’s strategic plans and focus. Any
forward-looking statements are based on management’s current
expectations of future events and are subject to a number of risks and
uncertainties that could cause actual results to differ materially and
adversely from those set forth in or implied by such forward-looking
statements. These risks and uncertainties include, but are not limited
to, the risk that the research programs for these targets or using the
technology licensed from Inhibrx will be unsuccessful and not result in
any viable product candidates, the risk that our collaboration
with Inhibrx will not continue or will not be successful, the risk of
cessation or delay of any planned clinical studies and/or our
development of our product candidates, and the risk that any one or more
of our product candidates will not be successfully developed and
commercialized. For a discussion of other risks and uncertainties, and
other important factors, any of which could cause our actual results to
differ from those contained in the forward-looking statements, see the
section entitled “Risk Factors” in our most recent quarterly report on
Form 10-Q, as well as discussions of potential risks, uncertainties, and
other important factors in our subsequent filings with the
Inhibrx Forward-Looking Statements
Certain statements in this press release are forward looking statements that involve a number of risks and uncertainties. These statements include statements about Inhibrx’s strategy, therapeutic candidates, including its sdAb platform. These statements represent Inhibrx’s judgements and expectations as of the date of this release. Actual results may differ due to a number of factors, including, but not limited to, the potential success and efficacy of Inhibrx’s therapeutic candidates. Inhibrx disclaims any intent or obligation to update these forward looking statements, other than as may be required by applicable law.
Source: bluebird bio, Inc.